Cannabidiol and Depression: Promise and Challenge in Building
an Evidence Base

Amelia   D.   Moser; Melissa   M.   Batt; Lorna   C.   Bidwell; Roselinde   H.   Kaiser
doi:10.2174/0122106766234102230919064455
Abstract

Background: Interest in the potential mental health effects of cannabidiol (CBD) has increased recently, with a surge in commercial and pharmaceutical development of CBD products and a concomitant rise in consumer use. However, despite the widespread and growing use of CBD products by adults and adolescents, the mental health effects of CBD remain largely unknown.
Objective: The goals of this review are: 1) to briefly review the evidence base for the mental health effects of CBD, using depression as an exemplar, and 2) to systematically outline complementary study designs needed to test CBD effects, together with challenges and special considerations related to each design.
Methods: This review integrates empirical findings related to CBD's effects on mental health outcomes with the literature on intervention trial design and current legal regulations pertaining to CBD.
Conclusion: Complementary controlled and observational studies of CBD are necessary to substantiate claims of mental health benefits, including for clinical depression and in pediatric populations. Investigators must consider challenges and opportunities specific to CBD as an intervention, including legal regulations, commercial or pharmaceutical product choice, dosing and bioavailability, and safety.
Keywords: Cannabidiol, cannabis, depression, clinical trial, observational study, adolescent.
« Previous Next »
[]
Abu-Sawwa, R.; Stehling, C. (2020), Epidiolex (cannabidiol) primer: Frequently asked questions for patients and caregivers. J. Pediatr. Pharmacol. Ther.,  25(1), 75-77.
 [http://dx.doi.org/10.5863/1551-6776-25.1.75] [PMID: 31897080]

[]
Altman, D.G.; Moher, D.; Schulz, K.F. (2012), Improving the reporting of randomised trials: The CONSORT Statement and beyond. Stat. Med.,  31(25), 2985-2997.
 [http://dx.doi.org/10.1002/sim.5402] [PMID: 22903776]

[]
Ameri, A. (1999), The effects of cannabinoids on the brain. Prog. Neurobiol.,  58(4), 315-348.
 [http://dx.doi.org/10.1016/S0301-0082(98)00087-2] [PMID: 10368032]

[]
Arndt, D.L.; de Wit, H. (2017), Cannabidiol does not dampen responses to emotional stimuli in healthy adults. Cannabis Cannabinoid Res.,  2(1), 105-113.
 [http://dx.doi.org/10.1089/can.2017.0014] [PMID: 28861510]

[]
Batalla, A.; Bos, J.; Postma, A.; Bossong, M.G. (2021), The impact of cannabidiol on human brain function: A systematic review. Front. Pharmacol.,  11, 618184.
 [http://dx.doi.org/10.3389/fphar.2020.618184] [PMID: 33551817]

[]
Bergamaschi, M.M.; Queiroz, R.H.C.; Chagas, M.H.N.; de Oliveira, D.C.G.; De Martinis, B.S.; Kapczinski, F.; Quevedo, J.; Roesler, R.; Schröder, N.; Nardi, A.E.; Martín-Santos, R.; Hallak, J.E.C.; Zuardi, A.W.; Crippa, J.A.S. (2011), Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology,  36(6), 1219-1226.
 [http://dx.doi.org/10.1038/npp.2011.6] [PMID: 21307846]

[]
Bhattacharyya, S.; Crippa, J.A.; Allen, P.; Martin-Santos, R.; Borgwardt, S.; Fusar-Poli, P.; Rubia, K.; Kambeitz, J.; O’Carroll, C.; Seal, M.L.; Giampietro, V.; Brammer, M.; Zuardi, A.W.; Atakan, Z.; McGuire, P.K. (2012), Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry,  69(1), 27-36.
 [http://dx.doi.org/10.1001/archgenpsychiatry.2011.161] [PMID: 22213786]

[]
Bhattacharyya, S.; Wilson, R.; Appiah-Kusi, E.; O’Neill, A.; Brammer, M.; Perez, J.; Murray, R.; Allen, P.; Bossong, M.G.; McGuire, P. (2018), Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A randomized clinical trial. JAMA Psychiatry,  75(11), 1107-1117.
 [http://dx.doi.org/10.1001/jamapsychiatry.2018.2309] [PMID: 30167644]

[]
Bidwell, L.C.; Karoly, H.C.; Torres, M.O.; Master, A.; Bryan, A.D.; Hutchison, K.E. (2022), A naturalistic study of orally administered vs. inhaled legal market cannabis: Cannabinoids exposure, intoxication, and impairment. Psychopharmacology,  239(2), 385-397.
 [http://dx.doi.org/10.1007/s00213-021-06007-2] [PMID: 34708254]

[]
Bidwell, L.C.; Mueller, R.;  YorkWilliams, S.L.; Hagerty, S.; Bryan, A.D.; Hutchison, K.E (2018), A novel observational method for assessing acute responses to cannabis: Preliminary validation using legal market strains. Cannabis Cannabinoid Res.,  3(1), 35-44.
 [http://dx.doi.org/10.1089/can.2017.0038] [PMID: 29607409]

[]
Bilbao, A.; Spanagel, R. (2022), Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med.,  20(1), 259.
 [http://dx.doi.org/10.1186/s12916-022-02459-1] [PMID: 35982439]

[]
Bonn-Miller, M.O.; Loflin, M.J.E.; Thomas, B.F.; Marcu, J.P.; Hyke, T.; Vandrey, R. (2017), Labeling accuracy of cannabidiol extracts sold online. JAMA,  318(17), 1708-1709.
 [http://dx.doi.org/10.1001/jama.2017.11909] [PMID: 29114823]

[]
Brown, J.D.; Goodin, A.J. (2021), Evidence in context: High risk of bias in medical cannabis and cannabinoid clinical trials dictates the need for cautious interpretation. Med. Cannabis Cannabinoids,  4(1), 63-66.
 [http://dx.doi.org/10.1159/000514732] [PMID: 34676351]

[]
Calapai, G.; Mannucci, C.; Chinou, I.; Cardia, L.; Calapai, F.; Sorbara, E.E.; Firenzuoli, B.; Ricca, V.; Gensini, G.F.; Firenzuoli, F. (2019), Preclinical and clinical evidence supporting use of cannabidiol in psychiatry. Evid. Based Complement. Alternat. Med.,  2019, 1-11.
 [http://dx.doi.org/10.1155/2019/2509129] [PMID: 31558911]

[]
Chagas, M.H.N.; Zuardi, A.W.; Tumas, V.; Pena-Pereira, M.A.; Sobreira, E.T.; Bergamaschi, M.M.; dos Santos, A.C.; Teixeira, A.L.; Hallak, J.E.C.; Crippa, J.A.S. (2014), Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. J. Psychopharmacol.,  28(11), 1088-1098.
 [http://dx.doi.org/10.1177/0269881114550355] [PMID: 25237116]

[]
Chesney, E.; Oliver, D.; Green, A.; Sovi, S.; Wilson, J.; Englund, A.; Freeman, T.P.; McGuire, P. (2020), Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology,  45(11), 1799-1806.
 [http://dx.doi.org/10.1038/s41386-020-0667-2] [PMID: 32268347]

[]
Cleophas, T.J.; Zwinderman, A.H.; Cleophas, T.F. , (2002). Crossover studies with continuous variables: Power analysis. Statistics Applied to Clinical Trials. In: Berlin, Germany Springerlink; 
 [http://dx.doi.org/10.1007/978-94-010-0337-7_12]

[]
Cumbo, N.; Boehmer, S.; Olympia, R.P.; Lessner, K.; Marshall, C.; Bozorghadad, S. (2021), Adverse effects associated with the use of cannabidiol (CBD) oil products on adolescents and young adults. Pediatrics,  147(3_MeetingAbstract), 211-211.
 [http://dx.doi.org/10.1542/peds.147.3MA3.211b]

[]
Cuttler, C.; Spradlin, A.; McLaughlin, R.J. (2018), A naturalistic examination of the perceived effects of cannabis on negative affect. J. Affect. Disord.,  235, 198-205.
 [http://dx.doi.org/10.1016/j.jad.2018.04.054] [PMID: 29656267]

[]
de Bruijn, S.E.M.; de Graaf, C.; Witkamp, R.F.; Jager, G. (2017), Explorative placebo-controlled double-blind intervention study with low doses of inhaled Δ9-tetrahydrocannabinol and cannabidiol reveals no effect on sweet taste intensity perception and liking in humans. Cannabis Cannabinoid Res.,  2(1), 114-122.
 [http://dx.doi.org/10.1089/can.2017.0018] [PMID: 28861511]

[]
Schier, A.; Ribeiro, N.; Coutinho, D.; Machado, S.; Arias-Carrión, O.; Crippa, J.; Zuardi, A.; Nardi, A.; Silva, A. (2014), Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of Cannabis sativa. CNS Neurol. Disord. Drug Targets,  13(6), 953-960.
 [http://dx.doi.org/10.2174/1871527313666140612114838] [PMID: 24923339]

[]
DEA. (2022).An informational outline of the controlled substances act.,  Practitioner’s Manual. Available From: https://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf

[]
Dorbian, I. , (2019). CBD market could reach $20 billion by 2024, says new study;  Available From: https://www.forbes.com/sites/irisdorbian/2019/05/20/cbd-market-could-reach-20-billion-by-2024-says-new-study/?sh=392d5bce49d0%0A

[]
Dubrow, G.A.; Pawar, R.S.; Srigley, C.; Fong Sam, J.; Talavera, C.; Parker, C.H.; Noonan, G.O. (2021), A survey of cannabinoids and toxic elements in hemp-derived products from the United States marketplace. J. Food Compos. Anal.,  97, 103800.
 [http://dx.doi.org/10.1016/j.jfca.2020.103800] [PMID: 35547641]

[]
El-Alfy, A.T.; Ivey, K.; Robinson, K.; Ahmed, S.; Radwan, M.; Slade, D.; Khan, I.; ElSohly, M.; Ross, S. (2010), Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav.,  95(4), 434-442.
 [http://dx.doi.org/10.1016/j.pbb.2010.03.004] [PMID: 20332000]

[]
Food & Drug Administration. , (2021). FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD);  Available From: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd

[]
Fusar-Poli, P.; Crippa, J.A.; Bhattacharyya, S.; Borgwardt, S.J.; Allen, P.; Martin-Santos, R.; Seal, M.; Surguladze, S.A.; O’Carrol, C.; Atakan, Z.; Zuardi, A.W.; McGuire, P.K. (2009), Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry,  66(1), 95-105.
 [http://dx.doi.org/10.1001/archgenpsychiatry.2008.519] [PMID: 19124693]

[]
Gáll, Z.; Farkas, S.; Albert, Á.; Ferencz, E.; Vancea, S.; Urkon, M.; Kolcsár, M. (2020), Effects of chronic cannabidiol treatment in the rat chronic unpredictable mild stress model of depression. Biomolecules,  10(5), 801.
 [http://dx.doi.org/10.3390/biom10050801] [PMID: 32455953]

[]
Goodman, S.; Wadsworth, E.; Schauer, G.; Hammond, D. (2022), Use and perceptions of cannabidiol products in Canada and in the United States. Cannabis Cannabinoid Res.,  7(3), 355-364.
 [http://dx.doi.org/10.1089/can.2020.0093] [PMID: 33998872]

[]
Guimarães, V.; Zuardi, A.W.; Del Bel, E.A.; Guimarães, F.S. (2004), Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci.,  75(5), 633-638.
 [http://dx.doi.org/10.1016/j.lfs.2004.01.015] [PMID: 15158372]

[]
Hotz, J.; Fehlmann, B.; Papassotiropoulos, A.; de Quervain, D.J.F.; Schicktanz, N.S. (2021), Cannabidiol enhances verbal episodic memory in healthy young participants: A randomized clinical trial. J. Psychiatr. Res.,  143, 327-333.
 [http://dx.doi.org/10.1016/j.jpsychires.2021.09.007] [PMID: 34536664]

[]
Hundal, H.; Lister, R.; Evans, N.; Antley, A.; Englund, A.; Murray, R.M.; Freeman, D.; Morrison, P.D. (2018), The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J. Psychopharmacol.,  32(3), 276-282.
 [http://dx.doi.org/10.1177/0269881117737400] [PMID: 29086614]

[]
Hutchison, K.E.; Bidwell, L.C.; Ellingson, J.M.; Bryan, A.D. (2019), Cannabis and health research: Rapid progress requires innovative research designs. Value Health,  22(11), 1289-1294.
 [http://dx.doi.org/10.1016/j.jval.2019.05.005] [PMID: 31708066]

[]
Iffland, K.; Grotenhermen, F. (2017), An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res.,  2(1), 139-154.
 [http://dx.doi.org/10.1089/can.2016.0034] [PMID: 28861514]

[]
Johnson, D.E. (2010), Crossover experiments. Wiley Interdiscip. Rev. Comput. Stat.,  2(5), 620-625.
 [http://dx.doi.org/10.1002/wics.109]

[]
Lawn, W.; Freeman, T.P.; Pope, R.A.; Joye, A.; Harvey, L.; Hindocha, C.; Mokrysz, C.; Moss, A.; Wall, M.B.; Bloomfield, M.A.P.; Das, R.K.; Morgan, C.J.A.; Nutt, D.J.; Curran, H.V. (2016), Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: An evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology,  233(19-20), 3537-3552.
 [http://dx.doi.org/10.1007/s00213-016-4383-x] [PMID: 27585792]

[]
Lawn, W.; Hill, J.; Hindocha, C.; Yim, J.; Yamamori, Y.; Jones, G.; Walker, H.; Green, S.F.; Wall, M.B.; Howes, O.D.; Curran, H.V.; Freeman, T.P.; Bloomfield, M.A.P. (2020), The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. J. Psychopharmacol.,  34(9), 969-980.
 [http://dx.doi.org/10.1177/0269881120944148] [PMID: 32755273]

[]
Leweke, F.M.; Piomelli, D.; Pahlisch, F.; Muhl, D.; Gerth, C.W.; Hoyer, C.; Klosterkötter, J.; Hellmich, M.; Koethe, D. (2012), Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry,  2(3), e94.
 [http://dx.doi.org/10.1038/tp.2012.15] [PMID: 22832859]

[]
Linares, I.M.; Zuardi, A.W.; Pereira, L.C.; Queiroz, R.H.; Mechoulam, R.; Guimarães, F.S.; Crippa, J.A. (2019), Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Revista Brasileira de Psiquiatria,  41(1), 9-14.

[]
Linge, R.; Jiménez-Sánchez, L.; Campa, L.; Pilar-Cuéllar, F.; Vidal, R.; Pazos, A.; Adell, A.; Díaz, Á. (2016), Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology,  103, 16-26.
 [http://dx.doi.org/10.1016/j.neuropharm.2015.12.017] [PMID: 26711860]

[]
McGuire, P.; Robson, P.; Cubala, W.J.; Vasile, D.; Morrison, P.D.; Barron, R.; Taylor, A.; Wright, S. (2018), Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am. J. Psychiatry,  175(3), 225-231.
 [http://dx.doi.org/10.1176/appi.ajp.2017.17030325] [PMID: 29241357]

[]
Merten, J.W.; Gordon, B.T.; King, J.L.; Pappas, C. (2020), Cannabidiol (CBD): Perspectives from Pinterest. Subst. Use Misuse,  55(13), 2213-2220.
 [http://dx.doi.org/10.1080/10826084.2020.1797808] [PMID: 32715862]

[]
Millar, S.A.; Stone, N.L.; Yates, A.S.; O’Sullivan, S.E. (2018), A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol.,  9, 1365.
 [http://dx.doi.org/10.3389/fphar.2018.01365] [PMID: 30534073]

[]
Millar, S.A.; Maguire, R.F.; Yates, A.S.; O’Sullivan, S.E. (2020), Towards better delivery of cannabidiol (CBD). Pharmaceuticals,  13(9), 219.
 [http://dx.doi.org/10.3390/ph13090219] [PMID: 32872355]

[]
Miller, I.; Scheffer, I.E.; Gunning, B.; Sanchez-Carpintero, R.; Gil-Nagel, A.; Perry, M.S.; Saneto, R.P.; Checketts, D.; Dunayevich, E.; Knappertz, V. (2020), Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: A randomized clinical trial. JAMA Neurol.,  77(5), 613-621.
 [http://dx.doi.org/10.1001/jamaneurol.2020.0073] [PMID: 32119035]

[]
Miller, O.S.; Elder, E.J., Jr; Jones, K.J.; Gidal, B.E. (2022), Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav.,  127, 108514.
 [http://dx.doi.org/10.1016/j.yebeh.2021.108514] [PMID: 34998268]

[]
Navarrete, F.; García-Gutiérrez, M.S.; Gasparyan, A.; Austrich-Olivares, A.; Manzanares, J. (2021), Role of cannabidiol in the therapeutic intervention for substance use disorders. Front. Pharmacol.,  12, 626010.
 [http://dx.doi.org/10.3389/fphar.2021.626010] [PMID: 34093179]

[]
NCCIH. (2018).Evaluating the therapeutic potential of	cannabinoids: How to conduct research within the current regulatory framework  Available From: https://www.nccih.nih.gov/news/events/evaluating-the-therapeutic-potential-of-cannabinoids-how-to-conduct-research-within-the-current-regulatory-framework#:~:text=%E2%80%9CEvaluating%20the%20therapeutic%20potential%20of%20cannabinoids%3A%20How%20to,processes%20and%20issues%20related%20to%20conducting%20cannabinoid%20research

[]
NIDA. (2015).Marijuana plant material available from the	NIDA drug supply program | National Institute on Drug Abuse (NIDA).  Available From: http://www.drugabuse.gov/researchers/research-resources/nida-drug-supply-program-dsp/marijuana-plant-material-available-nida-drug-supply-program

[]
NIDA. (2019).Drug supply program catalog, 29th edition october 2019 chemistry and pharmaceutics branch division of therapeutics and medical consequences national institute on drug abuse. NIH 

[]
, (2021). Frequently asked questions: NIH clinical trial definition;  Available From: https://grants.nih.gov/policy/clinical-trials/definition.htm

[]
O’Grady, C. (2020).Cannabis research database shows how U.S. funding focuses on harms of the drug. Science, 
 [http://dx.doi.org/10.1126/science.369.6508.1155]

[]
Pandolfo, P.; Silveirinha, V.; Santos-Rodrigues, A.; Venance, L.; Ledent, C.; Takahashi, R.N.; Cunha, R.A.; Köfalvi, A. (2011), Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur. J. Pharmacol.,  655(1-3), 38-45.
 [http://dx.doi.org/10.1016/j.ejphar.2011.01.013] [PMID: 21266173]

[]
Pauli, C.S.; Conroy, M.; Vanden Heuvel, B.D.; Park, S.H. (2020), Cannabidiol drugs clinical trial outcomes and adverse effects. Front. Pharmacol.,  11, 63.
 [http://dx.doi.org/10.3389/fphar.2020.00063] [PMID: 32161538]

[]
Perucca, E.; Bialer, M. (2020), Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs,  34(8), 795-800.
 [http://dx.doi.org/10.1007/s40263-020-00741-5] [PMID: 32504461]

[]
Piantadosi, S. (2005).Clinical Trials: A Methodologic Perspective. Hoboken, New Jersey Wiley-Interscience, 
 [http://dx.doi.org/10.1002/0471740136]

[]
Purcell, J.M.; Passley, T.M.; Leheste, J.R. (2022), The cannabidiol and marijuana research expansion act: Promotion of scientific knowledge to prevent a national health crisis. Lancet Reg Health Am,  14, 100325.
 [http://dx.doi.org/10.1016/j.lana.2022.100325]

[]
Quitkin, F.M.; Rabkin, J.D.; Markowitz, J.M.; Stewart, J.W.; McGrath, P.J.; Harrison, W. (1987), Use of pattern analysis to identify true drug response. A replication. Arch. Gen. Psychiatry,  44(3), 259-264.
 [http://dx.doi.org/10.1001/archpsyc.1987.01800150071009] [PMID: 3548638]

[]
Réus, G.Z.; Stringari, R.B.; Ribeiro, K.F.; Luft, T.; Abelaira, H.M.; Fries, G.R.; Aguiar, B.W.; Kapczinski, F.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Quevedo, J. (2011), Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatr.,  23(5), 241-248.
 [http://dx.doi.org/10.1111/j.1601-5215.2011.00579.x] [PMID: 25379896]

[]
Rossi, G.N.; Osório, F.L.; Morgan, C.J.A.; Crippa, J.A.S.; Bouso, J.C.; Rocha, J.M.; Zuardi, A.W.; Hallak, J.E.C.; Santos, R.G. (2020), The effects of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials. Neurosci. Biobehav. Rev.,  118, 236-246.
 [http://dx.doi.org/10.1016/j.neubiorev.2020.07.034] [PMID: 32745478]

[]
Russo, E.B. (2019), The case for the entourage effect and conventional breeding of clinical cannabis: No “Strain,” no gain. Front. Plant Sci.,  9, 1969.
 [http://dx.doi.org/10.3389/fpls.2018.01969] [PMID: 30687364]

[]
Sagar, K.A.; Dahlgren, M.K.; Lambros, A.M.; Smith, R.T.; El-Abboud, C.; Gruber, S.A. (2021), An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: Preliminary results. J. Int. Neuropsychol. Soc.,  27(6), 648-660.
 [http://dx.doi.org/10.1017/S1355617721000114] [PMID: 34261553]

[]
Sales, A.J.; Fogaça, M.V.; Sartim, A.G.; Pereira, V.S.; Wegener, G.; Guimarães, F.S.; Joca, S.R.L. (2019), Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Mol. Neurobiol.,  56(2), 1070-1081.
 [http://dx.doi.org/10.1007/s12035-018-1143-4] [PMID: 29869197]

[]
Sartim, A.G.; Guimarães, F.S.; Joca, S.R.L. (2016), Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex—Possible involvement of 5-HT1A and CB1 receptors. Behav. Brain Res.,  303, 218-227.
 [http://dx.doi.org/10.1016/j.bbr.2016.01.033] [PMID: 26801828]

[]
Sartim, A.G.; Sales, A.J.; Guimarães, F.S.; Joca, S.R.L. (2018), Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test. J. Psychopharmacol.,  32(8), 922-931.
 [http://dx.doi.org/10.1177/0269881118784877] [PMID: 29968502]

[]
Schiavon, A.P.; Bonato, J.M.; Milani, H.; Guimarães, F.S.; Weffort de Oliveira, R.M. (2016), Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog. Neuropsychopharmacol. Biol. Psychiatry,  64, 27-34.
 [http://dx.doi.org/10.1016/j.pnpbp.2015.06.017] [PMID: 26187374]

[]
Shbiro, L.; Hen-Shoval, D.; Hazut, N.; Rapps, K.; Dar, S.; Zalsman, G.; Mechoulam, R.; Weller, A.; Shoval, G. (2019), Effects of cannabidiol in males and females in two different rat models of depression. Physiol. Behav.,  201, 59-63.
 [http://dx.doi.org/10.1016/j.physbeh.2018.12.019] [PMID: 30571957]

[]
Sholler, D.J.; Spindle, T.R.; Cone, E.J.; Goffi, E.; Kuntz, D.; Mitchell, J.M.; Winecker, R.E.; Bigelow, G.E.; Flegel, R.R.; Vandrey, R. (2022), Urinary pharmacokinetic profile of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and their metabolites following oral and vaporized CBD and vaporized CBD-dominant cannabis administration. J. Anal. Toxicol.,  46(5), 494-503.
 [http://dx.doi.org/10.1093/jat/bkab059] [PMID: 34089060]

[]
Shoval, G.; Shbiro, L.; Hershkovitz, L.; Hazut, N.; Zalsman, G.; Mechoulam, R.; Weller, A. (2016), Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology,  73(2), 123-129.
 [http://dx.doi.org/10.1159/000443890] [PMID: 27010632]

[]
Silmore, L.H.; Willmer, A.R.; Capparelli, E.V.; Rosania, G.R. (2021), Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. Pharmacotherapy,  41(4), 405-420.
 [http://dx.doi.org/10.1002/phar.2512] [PMID: 33583102]

[]
Silote, G.P.; Sartim, A.; Sales, A.; Eskelund, A.; Guimarães, F.S.; Wegener, G.; Joca, S. (2019), Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J. Chem. Neuroanat.,  98, 104-116.
 [http://dx.doi.org/10.1016/j.jchemneu.2019.04.006] [PMID: 31039391]

[]
Silva Junior, E.A.; Medeiros, W.M.B.; Santos, J.P.M.; Sousa, J.M.M.; Costa, F.B.; Pontes, K.M.; Borges, T.C.; Espínola Neto Segundo, C.; Andrade e Silva, A.H.; Nunes, E.L.G.; Torro, N.; Rosa, M.D.; Albuquerque, K.L.G.D. (2022)Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind and controlled placebo clinical trial. Trends Psychiatry Psychother.,  , 44.
 [http://dx.doi.org/10.47626/2237-6089-2021-0396] [PMID: 35617670]

[]
Soleymanpour, M.; Saderholm, S.; Kavuluru, R. Therapeutic claims in cannabidiol (CBD) marketing messages on Twitter. 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM),  Houston, TX, USA(2021), pp. 3083-3088.
 [http://dx.doi.org/10.1109/BIBM52615.2021.9669404]

[]
Taylor, L.; Gidal, B.; Blakey, G.; Tayo, B.; Morrison, G. (2018), A phase I, randomized, double-blind, llacebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs,  32(11), 1053-1067.
 [http://dx.doi.org/10.1007/s40263-018-0578-5] [PMID: 30374683]

[]
Tran, T.; Kavuluru, R. (2020), Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products. Int. J. Drug Policy,  77, 102688.
 [http://dx.doi.org/10.1016/j.drugpo.2020.102688] [PMID: 32092666]

[]
USNLM. (2022).FDAAA 801 and the final rule.,  Available From: https://clinicaltrials.gov/ct2/manage-recs/fdaaa

[]
Wade, D.T.; Robson, P.; House, H.; Makela, P.; Aram, J. (2003), A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil.,  17(1), 21-29.
 [http://dx.doi.org/10.1191/0269215503cr581oa] [PMID: 12617376]

[]
Wagoner, K.G.; Lazard, A.J.; Romero-Sandoval, E.A.; Reboussin, B.A. (2021), Health claims about cannabidiol products: A retrospective analysis of u.s. food and drug administration warning letters from 2015 to 2019. Cannabis Cannabinoid Res.,  6(6), 559-563.
 [http://dx.doi.org/10.1089/can.2020.0166] [PMID: 34142863]

[]
Wheeler, M.; Merten, J.W.; Gordon, B.T.; Hamadi, H. (2020), CBD (cannabidiol) product attitudes, knowledge, and use among young adults. Subst. Use Misuse,  55(7), 1138-1145.
 [http://dx.doi.org/10.1080/10826084.2020.1729201] [PMID: 32093530]

[]
Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; Schmidlkofer, S.; Westwood, M.; Kleijnen, J. (2015), Cannabinoids for medical use: A systematic review and meta-analysis. JAMA,  313(24), 2456-2473.
 [http://dx.doi.org/10.1001/jama.2015.6358] [PMID: 26103030]

[]
Wieckiewicz, G.; Stokłosa, I.; Stokłosa, M.; Gorczyca, P.; Pudlo, R (2022), Cannabidiol (CBD) in the self-treatment of depression-Exploratory study and a new phenomenon of concern for psychiatrists. Front. Psychiatry,  13, 837946.
 [http://dx.doi.org/10.3389/fpsyt.2022.837946] [PMID: 35392393]

[]
Williams, N.N.B.; Ewell, T.R.; Abbotts, K.S.S.; Harms, K.J.; Woelfel, K.A.; Dooley, G.P.; Weir, T.L.; Bell, C. (2021), Comparison of five oral cannabidiol preparations in adult humans: Pharmacokinetics, body composition, and heart rate variability. Pharmaceuticals,  14(1), 35.
 [http://dx.doi.org/10.3390/ph14010035] [PMID: 33418866]

[]
Wilson, R.; Bossong, M.G.; Appiah-Kusi, E.; Petros, N.; Brammer, M.; Perez, J.; Allen, P.; McGuire, P.; Bhattacharyya, S. (2019), Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl. Psychiatry,  9(1), 203.
 [http://dx.doi.org/10.1038/s41398-019-0534-2] [PMID: 31439831]

[]
Zanelati, T.V.; Biojone, C.; Moreira, F.A.; Guimarães, F.S.; Joca, S.R.L. (2010), Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br. J. Pharmacol.,  159(1), 122-128.
 [http://dx.doi.org/10.1111/j.1476-5381.2009.00521.x] [PMID: 20002102]
Rights & Permissions Print Cite
Article Metrics
15
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0122106766234102230919064455	Print ISSN 2210-6766
Publisher Name Bentham Science Publisher	Online ISSN 2210-6774
Adolescent Psychiatry

Cannabidiol and Depression: Promise and Challenge in Building an Evidence Base

Abstract

Related Journals

Related Books
